Next Generation Sequencing Market Summary
As per MRFR analysis, the Global Next Generation Sequencing Market was valued at 14.39 USD Billion in 2023 and is projected to grow to 50 USD Billion by 2035, with a CAGR of 10.94% from 2025 to 2035. The market is driven by the rising prevalence of genetic disorders, technological advancements, and increasing applications in drug discovery and personalized medicine.
Key Market Trends & Highlights
The Next Generation Sequencing Market is witnessing transformative growth driven by technological innovations and increased applications.
- Market size in 2024: 15.96 USD Billion; projected to reach 50 USD Billion by 2035.
- Sequencing by Synthesis technology valued at 6.0 USD Billion in 2024; expected to rise to 18.5 USD Billion by 2035.
- North America leads the market with a valuation of 8.5 USD Billion in 2024; projected to reach 28.0 USD Billion by 2035.
- Rising applications in diagnostics and personalized medicine are enhancing market growth.
Market Size & Forecast
2023 Market Size: USD 14.39 Billion
2024 Market Size: USD 15.96 Billion
2035 Market Size: USD 50 Billion
CAGR (2025-2035): 10.94%
Largest Regional Market Share in 2024: North America.
Major Players
Key players include Thermo Fisher Scientific, Pacific Biosciences, QIAGEN, Roche, BGI Group, Illumina, Danaher Corporation, PerkinElmer, Agilent Technologies, and Oxford Nanopore Technologies.
Key Next Generation Sequencing Market Trends Highlighted
The Next Generation Sequencing Market is witnessing significant growth driven by advancements in technology and increased demand for genomic research. Key market drivers include the rising prevalence of genetic disorders and the growing focus on precision medicine. As healthcare systems around the world emphasize personalized treatment plans, the need for efficient and accurate sequence analysis has surged. Furthermore, government initiatives and funding for genomic research are bolstering the capabilities in this field, making NGS more accessible to various research institutions and laboratories globally. Opportunities to be explored include the expanding application of next-generation sequencing in oncology, infectious disease detection, and rare genetic disorders.
Non-invasive prenatal testing is experiencing a significant increase in popularity among expectant parents. Furthermore, the analysis and interpretation of data are being improved by the development of bioinformatics tools and software, which has rendered NGS a critical instrument for both researchers and clinicians. The increasing incorporation of artificial intelligence into data processing presents a new opportunity to enhance the efficiency of genetic research. The recent trends underscore the decrease in costs associated with sequencing technology, which has facilitated a more extensive range of research opportunities for researchers worldwide. The global reach of this technology is being expanded by the emergence of portable NGS devices, which is also making sequencing feasible in remote areas.
Next-generation sequencing applications are being expanded and innovation is being promoted by the trend toward collaboration among academic institutions, biotech companies, and public health organizations. This collaborative approach is indispensable for guaranteeing that the complete potential of NGS is realized in a variety of sectors, including agricultural applications and clinical diagnostics.
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
Next Generation Sequencing Market Drivers
Rising Demand for Personalized Medicine
The Next Generation Sequencing Market Industry is significantly propelled by the growing trend towards personalized medicine. With advancements in genomics, healthcare providers are increasingly adopting tailored therapies based on individual genetic profiles. According to a report from the Global Alliance for Genomics and Health, over 50% of cancer treatments are now being customized to the patient's genomic information. This shift towards personalized approaches is vital for improving treatment outcomes and is greatly promoting the adoption of next-generation sequencing technologies.
Established organizations such as the National Institutes of Health in the United States have recognized this trend, advocating for genomic medicine, which further enhances the demand for next-generation sequencing technologies in the healthcare environment. The growth in genetically-targeted therapies not only improves patient care but also drives investments in research and development by pharmaceutical companies seeking to innovate new drugs based on genomic insights, creating a robust market environment for next-generation sequencing.
Increased Application in Cancer Research
The increasing application of next-generation sequencing in cancer research is another critical driver for the Next Generation Sequencing Market Industry. The World Health Organization projects that cancer cases will rise by 70% over the next two decades, underscoring an urgent need for advanced diagnostics and treatment options. This escalating cancer prevalence is encouraging research institutions and pharmaceutical companies, including organizations like the American Association for Cancer Research, to utilize next-generation sequencing for identifying genetic mutations that contribute to cancer progression.
Such advancements are crucial as they facilitate the development of more effective therapeutic strategies and contribute to a deeper understanding of oncogenomics, thereby fostering growth in the next-generation sequencing market.
Technological Advancements and Reductions in Sequencing Costs
Continuous technological advancements and significant reductions in sequencing costs are pivotal for the growth of the Next Generation Sequencing Market Industry. The cost of sequencing a human genome has plummeted from over $100 million in 2001 to approximately $1,000 today, according to data from the National Human Genome Research Institute. This drastic cost reduction has made sequencing technology more accessible to research institutions and clinical laboratories globally, accelerating the implementation of next-generation sequencing across various applications, including disease detection, genetic testing, and pharmacogenomics.
Prominent companies such as Illumina and Thermo Fisher Scientific are consistently innovating and releasing next-generation sequencing platforms that are not only cost-effective but also yield higher accuracy and greater throughput, thus driving the widespread adoption and growth of the market.
Growing Focus on Genomic Research and Development
The Next Generation Sequencing Market Industry is also thriving due to the increasing focus on genomic research and development as governments and private entities ramp up investment in life sciences. For instance, the European Commission, in its Horizon Europe research program, has allocated substantial funding to initiatives aimed at enhancing genomic research and healthcare applications. This commitment has led to a surge in projects focusing on genetics, genomics, and biotechnology.
The spotlight on genomic studies significantly amplifies the demand for next-generation sequencing solutions, as researchers need these advanced tools to analyze vast amounts of genomic data. This trend reflects a global shift toward integrating genomics into healthcare solutions, ensuring further growth in the next-generation sequencing landscape.
Next Generation Sequencing Market Segment Insights
Next Generation Sequencing Market Technology Insights
The Next Generation Sequencing Market, particularly focusing on the Technology segment, has shown robust growth and significant potential in recent years. By 2024, the Technology segment is expected to contribute alongside various advanced methodologies like Sequencing by Synthesis, Ion Semiconductor Sequencing, Single-Molecule Real-Time Sequencing, Nanopore Sequencing, and Other Technologies. Sequencing by Synthesis stands out prominently, valued at 6.0 USD Billion in 2024 and projected to reach 18.9 USD Billion by 2035, capturing a majority holding in the market due to its efficiency and reliability in generating comprehensive genomic data.
Ion Semiconductor Sequencing also plays a crucial role, expected to be valued at 3.5 USD Billion in 2024, with a projection of reaching 11.0 USD Billion in 2035. This method is favored for its speed and cost-effectiveness, which are essential for large-scale genomic research. Moreover, Single-Molecule Real-Time Sequencing, valued at 2.5 USD Billion in 2024 and anticipated to rise to 7.5 USD Billion by 2035, is gaining traction due to its ability to sequence DNA without amplification, allowing for longer reads and thus offering deeper insights into genetic variations.
Nanopore Sequencing, although slightly lower in market valuation at 1.96 USD Billion in 2024, is projected to grow to 6.0 USD Billion by 2035, showcasing its unique capability of providing real-time sequencing data. Lastly, Other Technologies provide an additional layer of innovation, valued at 2.0 USD Billion in 2024, expected to grow to 6.6 USD Billion by 2035, emphasizing the diverse methodologies evolving within the Next Generation Sequencing Market. The market overall demonstrates various trends, such as the increasing demand for personalized medicine, accelerating advancements in genomic research, and rising funding by governments for genetic studies which all contribute to a dynamic environment for the Technology segment's growth.With ongoing technological improvements and a growing number of applications in healthcare, agriculture, and bioinformatics, the Next Generation Sequencing Market is poised for continual expansion and presents invaluable opportunities for stakeholders in the industry.
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
Next Generation Sequencing Market Product Type Insights
The Next Generation Sequencing Market is projected to reach a value of 15.96 USD Billion by 2024, with significant growth observed across various product types that cater to diverse applications in genomics. Key segments in this market include Reagents, Instruments, Software, and Services, which together represent a comprehensive landscape driving innovation and efficiency in genetic analysis. Reagents play a crucial role as they are essential for preparing samples and conducting sequencing, emphasizing their importance in the market's structure.
Instruments, on the other hand, form the backbone of sequencing capabilities, enabling high-throughput analysis that meets the increasing demands of research, clinical diagnostics, and personalized medicine. Software solutions are vital for data analysis, interpretation, and management, making them a significant contributor to enhancing workflow efficiency. Services related to next generation sequencing encompass a range of support options, from project consultation to data management, further strengthening the market's infrastructure. These factors collectively shape the Next Generation Sequencing Market, responding to urgent needs in medical research, disease prevention, and therapeutic development across the globe, with a strong focus on advancing our understanding of the genetic basis of health and disease.
Next Generation Sequencing Market Application Insights
The Next Generation Sequencing Market focused on the Application segment is experiencing noteworthy growth, with a projected valuation of 15.96 billion USD by 2024. This expansion can be attributed to the increasing demand for advanced diagnostic tools and personalized medicine solutions which utilize sequencing technologies to enhance healthcare outcomes. Each Application area plays a prominent role; Diagnostics is becoming essential for identifying diseases at earlier stages, boosting patient prognosis and treatment effectiveness. Research activities leverage Next Generation Sequencing to accelerate discoveries in genomics, aiding in the study of genetic variations and their implications.
Personalized Medicine focuses on tailoring treatment plans based on individual genetic profiles, significantly improving therapeutic efficacy. Agrigenomics is gaining traction as well, emphasizing the importance of genomics in improving crop yields and resilience against disease and environmental challenges. These aspects collectively underscore the significance of the Next Generation Sequencing Market revenue as it aligns with the compelling need for precision in diagnostics, research, and agriculture, driving growth and opportunity across various sectors.The continuing advancements in technology and decreasing costs further bolster market growth, making it a critical area for innovation and development in the coming years.
Next Generation Sequencing Market End Use Insights
The Next Generation Sequencing Market is witnessing substantial growth, expected to reach a valuation of 15.96 USD Billion by 2024. This growth is largely driven by increasing investments in research and development across various end-use sectors. Academic institutes play a pivotal role in advancing genomic research, utilizing Next Generation Sequencing technologies for a wide range of studies, from disease mechanisms to personalized medicine. Pharmaceutical companies are significantly embracing these technologies to streamline drug discovery and development processes, thus enhancing their competitive edge.
Similarly, biotechnology companies leverage Next Generation Sequencing for innovative applications in genomics, which is vital for their product development and market positioning. Hospitals and clinics are increasingly incorporating Next Generation Sequencing for diagnostic purposes, thereby improving patient outcomes through precision medicine. The combination of these end-use sectors not only fuels the Next Generation Sequencing Market revenue but also reflects its multifaceted application, indicating a robust and dynamic industry landscape.With the market driven by technological advancements and increased affordability, the adoption rates are expected to surge, presenting abundant opportunities for growth in the coming years.
Next Generation Sequencing Market Regional Insights
The Next Generation Sequencing Market has shown considerable growth across various regions, leading to significant market revenue in North America, Europe, South America, Asia Pacific, and the Middle East and Africa. By 2024, North America is projected to hold a valuation of 6.0 USD Billion, dominating the market due to advanced technological infrastructure and substantial investments in Research and Development, anticipating to reach 18.0 USD Billion by 2035. Following North America, Europe shows strong potential with a value of 4.5 USD Billion in 2024, rising to 13.5 USD Billion in 2035, driven by increased genomic research and a growing focus on personalized medicine.
Meanwhile, Asia Pacific is expected to represent a significant portion of the market, valued at 3.5 USD Billion in 2024 and reaching 10.5 USD Billion by 2035, fueled by expanding healthcare sectors and enhanced scientific collaborations. South America and the Middle East and Africa, while smaller markets with values of 1.3 USD Billion and 1.66 USD Billion in 2024 respectively, show promising growth trajectories due to rising healthcare awareness and investments in biotechnology, expected to increase to 4.0 USD Billion by 2035 for both regions.Overall, the Next Generation Sequencing Market segmentation reveals varied growth dynamics influenced by regional advancements in genomics, biotechnology innovations, and healthcare policies, facilitating unique opportunities across each market segment.
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
Next Generation Sequencing Market Key Players and Competitive Insights
The Next Generation Sequencing Market is characterized by rapid advancements and intense competition among key players. This market has witnessed significant growth driven by technological innovations, increasing applications of sequencing technologies, and the growing demand for personalized medicine and genomics research. Companies are actively investing in research and development and forming strategic partnerships to enhance their product offerings and expand their market reach. The competitive landscape is marked by a blend of established players and emerging firms, each striving to capitalize on the expanding opportunities within the genomics and diagnostics sectors. As the demand for efficient and cost-effective sequencing solutions continues to increase, companies are focusing on differentiating their offerings through innovative technologies and comprehensive service packages to maintain their competitive edge.
Oxford Nanopore Technologies has established a significant presence in the Next Generation Sequencing Market through its innovative sequencing technology that distinguishes it from competitors. The company's strength lies in its real-time sequencing capabilities, which offer researchers unparalleled speed and versatility in genomic analysis. Its portable sequencing solutions cater to diverse applications across academic, clinical, and pharmaceutical research, facilitating greater accessibility and ease of use in various settings. In addition to its technological advantages, Oxford Nanopore Technologies has built a strong reputation for its commitment to customer support and training, allowing users to maximize the benefits of their sequencing platforms. This focus on customer engagement, along with a robust product portfolio, positions the company favorably in an increasingly competitive landscape.
Thermo Fisher Scientific plays a pivotal role in the Next Generation Sequencing Market, well-known for its comprehensive suite of sequencing products and services. The company's broad portfolio includes key offerings such as Ion Proton and Ion GeneStudio S5 series sequencers, which are designed to meet varying throughput needs of researchers. Thermo Fisher Scientific leverages its extensive experience in life sciences and diagnostics to develop high-quality products tailored to the evolving requirements of genomic research. Its strengths encompass a large global distribution network and strategic mergers and acquisitions that have enhanced its technological capabilities and market position. By continuously expanding its product offerings and investing in next-generation technologies, Thermo Fisher Scientific aims to maintain its leadership status in this dynamic market while addressing the needs of a diverse customer base across various regions.
Key Companies in the Next Generation Sequencing Market Include
- Oxford Nanopore Technologies
- Thermo Fisher Scientific
- PerkinElmer
- Agilent Technologies
- Droplet Genomics
- BGI
- Genomatix
- Pacific Biosciences
- Qiagen
- Roche
- 10X Genomics
- Ruggedized Digital DNA Technologies
- Illumina
- BioRad Laboratories
Next Generation Sequencing Market Industry Developments
The Next Generation Sequencing Market has seen significant developments recently, particularly with notable advancements from key players. Oxford Nanopore Technologies continues to innovate with new sequencing technologies aimed at enhancing real-time data acquisition and analysis. Thermo Fisher Scientific has made strides in expanding its NGS portfolio by launching new instruments that facilitate high-throughput sequencing. In the merger and acquisition landscape, Illumina announced the acquisition of GRAIL in August 2021, focusing on early cancer detection through liquid biopsy technology, which is expected to strengthen its market position.
Meanwhile, in July 2023, Roche acquired GenMark Diagnostics to bolster its molecular diagnostics capabilities, further integrating its NGS offerings into the diagnostics market. The overall market is experiencing growth fueled by increased applications in personalized medicine, cancer research, and genetic testing, with the valuation of companies like Pacific Biosciences and Qiagen also reflecting positive trends in this sector. Additionally, regulatory support for genomic testing amid rising healthcare priorities is further driving investment and innovation across the Next Generation Sequencing Market, indicating a vibrant landscape for growth and collaboration among industry leaders in the coming years.
Next Generation Sequencing Market Segmentation Insights
Next Generation Sequencing Market Technology Outlook
- Sequencing by Synthesis
- Ion Semiconductor Sequencing
- Single-Molecule Real-Time Sequencing
- Nanopore Sequencing
- Other Technologies
Next Generation Sequencing Market Product Type Outlook
- Reagents
- Instruments
- Software
- Services
Next Generation Sequencing Market Application Outlook
- Diagnostics
- Research
- Personalized Medicine
- Agrigenomics
Next Generation Sequencing Market End Use Outlook
- Academic Institutes
- Pharmaceutical Companies
- Biotechnology Companies
- Hospitals and Clinics
Next Generation Sequencing Market Regional Outlook
- North America
- Europe
- South America
- Asia Pacific
- Middle East and Africa
|
Report Attribute/Metric
|
Details
|
|
Market Size 2023
|
14.39(USD Billion)
|
|
Market Size 2024
|
15.96(USD Billion)
|
|
Market Size 2035
|
50.0(USD Billion)
|
|
Compound Annual Growth Rate (CAGR)
|
10.94% (2025 - 2035)
|
|
Report Coverage
|
Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
|
|
Base Year
|
2024
|
|
Market Forecast Period
|
2025 - 2035
|
|
Historical Data
|
2019 - 2024
|
|
Market Forecast Units
|
USD Billion
|
|
Key Companies Profiled
|
Oxford Nanopore Technologies, Thermo Fisher Scientific, PerkinElmer, Agilent Technologies, Droplet Genomics, BGI, Genomatix, Pacific Biosciences, Qiagen, Roche, 10X Genomics, Ruggedized Digital DNA Technologies, Illumina, BioRad Laboratories
|
|
Segments Covered
|
Technology, Product Type, Application, End Use, Regional
|
|
Key Market Opportunities
|
Personalized medicine advancements, Genomic data analysis growth, Cancer research innovations, Cost reduction in sequencing, Emerging applications in agriculture
|
|
Key Market Dynamics
|
Technological advancements in sequencing, Increasing applications in genomics, Rising demand for personalized medicine, Growing research funding in biotechnology, Decreasing sequencing costs and turnaround times
|
|
Countries Covered
|
North America, Europe, APAC, South America, MEA
|
Next Generation Sequencing Market Highlights:
Frequently Asked Questions (FAQ) :
The Next Generation Sequencing Market is expected to be valued at 15.96 USD Billion in 2024.
By 2035, the Next Generation Sequencing Market is projected to reach 50.0 USD Billion.
The expected CAGR for the Next Generation Sequencing Market from 2025 to 2035 is 10.94%.
North America is expected to hold the largest market share with a value of 6.0 USD Billion in 2024.
The Asia Pacific region is projected to value 10.5 USD Billion by 2035.
Sequencing by Synthesis technology is expected to be valued at 6.0 USD Billion in 2024 and 18.9 USD Billion in 2035.
Key players in the market include Oxford Nanopore Technologies, Thermo Fisher Scientific, and Illumina among others.
Ion Semiconductor Sequencing is forecasted to reach a market size of 11.0 USD Billion by 2035.
Current challenges include regulatory hurdles, while opportunities arise from increasing applications in genomics and personalized medicine.
The Europe region is expected to see a significant growth rate, reaching 13.5 USD Billion by 2035.
